基层慢阻肺患者两年呼吸科住院风险预后评分:BLISS研究
该研究基于BLISS队列开发并内部验证了预测慢阻肺患者两年内呼吸科住院风险的BLISS评分,并在ECLIPSE国际队列和CPRD Aurum数据库中外部验证。评分包含6个预测因子,内部验证乐观校正C统计量为0.73(95%CI 0.70-0.77),外部验证C统计量在0.71-0.73之间,校准良好,且净获益优于单个预测因子和Bertens评分。
要点
- BLISS评分含6个预测因子:年龄、CAT评分、既往12个月呼吸科住院、BMI、糖尿病、FEV1%预计值。
- 内部验证乐观校正C统计量0.73(95%CI 0.70-0.77),外部验证C统计量0.71-0.73。
- 净获益分析显示BLISS评分优于单个预测因子和Bertens评分(C=0.68,95%CI 0.65-0.71)。
核心结论
- BLISS评分在来自不同机构、地域和COPD严重程度的队列中,对个体两年内呼吸科住院风险显示出良好预测性能。
- 需要影响评估研究来充分探讨该评分在临床实践中的应用。
研究设计与样本
- 研究为模型开发与验证研究,使用BLISS队列(1894例新发和现有COPD患者)进行开发与内部验证。
- 外部验证使用ECLIPSE国际队列(1749例中重度至极重度COPD患者)和CPRD Aurum数据库与医院统计关联数据(27 340例COPD患者)。
- 采用多变量逻辑回归从23个候选预测因子中建模,并用自举法进行内部验证以校正过拟合和乐观偏倚。
主要发现
- 最终保留6个预测因子构成BLISS评分:年龄、COPD评估测试评分、既往12个月呼吸科住院、体重指数、糖尿病、FEV1占预计值百分比。
- 内部验证乐观校正C统计量为0.73(95%CI 0.70-0.77),外部验证ECLIPSE C=0.73(95%CI 0.71-0.76),CPRD C=0.71(95%CI 0.70-0.72)。
- 校准斜率:BLISS为0.87(95%CI 0.73-1.02),CPRD为0.89(95%CI 0.85-0.93),ECLIPSE为0.92(95%CI 0.79-1.05)。
- CPRD分层分析显示评分在不同亚组中稳健。
- 净获益分析显示BLISS评分优于单个预测因子和Bertens评分(C=0.68,95%CI 0.65-0.71;校准斜率0.68,95%CI 0.56-0.81)。
关键数值与推荐
- BLISS评分用于估计个体两年内呼吸科住院风险,预测因子包括年龄、CAT评分、既往12个月呼吸科住院、BMI、糖尿病、FEV1%预计值。
- 模型区分度:内部验证乐观校正C统计量0.73(95%CI 0.70-0.77);外部验证ECLIPSE C=0.73(95%CI 0.71-0.76),CPRD C=0.71(95%CI 0.70-0.72)。
- 校准斜率:BLISS 0.87(95%CI 0.73-1.02),CPRD 0.89(95%CI 0.85-0.93),ECLIPSE 0.92(95%CI 0.79-1.05)。
- 与Bertens评分比较:BLISS评分C统计量0.73(95%CI 0.71-0.76)优于Bertens评分C=0.68(95%CI 0.65-0.71)。
临床怎么用
- BLISS评分可用于基层医疗中估计COPD患者两年内呼吸科住院风险,评分中四个变量在基层病历中易于获取,两个变量部分可用但易于收集。
- 该评分在临床相关风险阈值范围内净获益优于单个预测因子和Bertens评分,但需影响评估研究进一步验证临床使用效果。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To predict the two year risk of respiratory admission to hospital among individuals with chronic obstructive pulmonary disease (COPD), with the development and validation (internal and external) of a prognostic score. DESIGN: Model development and validation in population cohorts. SETTING: Birmingham Lung Improvement Studies (BLISS) cohort of new and existing patients with COPD in primary care (model development and internal validation); Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) international cohort and UK primary care Clinical Practice Research Datalink (CPRD) Aurum database linked with Hospital Episode Statistics (external validation). PARTICIPANTS: 1894 patients with new and existing COPD from BLISS cohort; 1749 patients with moderate to very severe COPD from ECLIPSE cohort; 27 340 patients with COPD from CPRD Aurum database linked with Hospital Episode Statistics. MAIN OUTCOME MEASURES: One or more respiratory admissions within two years of cohort entry for development, internal validation, and external validation in CPRD; severe exacerbation within two years for external validation in ECLIPSE cohort. The model was developed from 23 candidate predictors by using multivariable logistic regression with bootstrapping for internal validation and adjustment for overfitting and optimism. Discrimination and calibration were assessed at each stage. Net benefit of the score (clinical utility) was examined across a range clinically relevant risk thresholds compared with use of individual score components. Subgroup and sensitivity analyses were conducted in the CPRD. The BLISS score was directly compared with the Bertens' score in the ECLIPSE cohort. Clinical implementation was explored with relevant stakeholders. RESULTS: Six predictors were retained (age, COPD Assessment Test score, respiratory admissions in the previous 12 months, body mass index, diabetes, forced expiratory volume in 1 second % predicted) to form the BLISS score for estimating an individual's two year risk of respiratory admission. The score had similar discrimination performance on internal validation (optimism adjusted C statistic 0.73 (95% confidence interval 0.70 to 0.77)) and external validation (ECLIPSE: C=0.73 (0.71 to 0.76); CPRD: C=0.71 (0.70 to 0.72)) and good calibration performance in the BLISS (slope=0.87 (95% confidence interval 0.73 to 1.02), CPRD (0.89 (0.85 to 0.93)), and ECLIPSE (0.92 (0.79 to 1.05) cohorts). Stratified analysis in the CPRD cohort showed that it was robust in different population subgroups. Net benefit analyses showed superiority of the BLISS score over individual predictors and the Bertens' score (C=0.68 (0.65 to 0.71); calibration slope 0.68 (0.56 to 0.81)). CONCLUSIONS: The BLISS score showed good performance in estimating individual risk of respiratory admission (within two years) in cohorts containing patients from different settings and geographical locations and with different severities of COPD. Four of the included six variables are readily available in primary care records, and two are partially available but easy to collect. Impact evaluations are now needed to fully study use of the score in clinical care. STUDY REGISTRATION: ECLIPSE ClinicalTrials.gov NCT00292552.
引用
- Jordan RE, Keene SJ, Franssen FME, et al. Prognostic score for predicting respiratory admissions among patients with chronic obstructive pulmonary disease in primary care: development and validation in population cohorts (Birmingham Lung Improvement Studies (BLISS)). BMJ. 2026. PMID: 41786356. doi:10.1136/bmj-2025-084521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。